Respiratory Inhalers Market is Growing at a CAGR of 7% by 2027

Global Respiratory Inhalers Market is witnessing highest CAGR growth of 7.0% and expected to reach USD 53.1 Bn by 2027.

The global respiratory inhalers market is growing significantly due to rise in adoption of respiratory products and growing prevalence for chronic pulmonary diseases such as nasal congestion, asthma, and COPD. Moreover, increase in government spending on technological advancement for developing medical devices, spread of awareness regarding techno-therapies, early-diagnosis of respiratory diseases, and rising funds for research facilities fuels the growth of the market.

Emergence of new, extremely sensitive technologies in medical device segment boosts the growth of the ecosystem across the globe. In addition to this, rising air pollution across the globe, increasing number of vehicles and growing industrialization contribute to the increasing respiratory diseases which further leverage the growth of respiratory inhalers market. However, lack of product awareness and stringent government regulations for medical device approvals hinder the growth of respiratory inhalers industry.

According to WHO, ~66 Mn of people suffer from COPD and about ~3 Mn of people die every year with chronic obstructive pulmonary disease, making it the 3rd leading cause of death across the globe. Moreover, more than ~335 Mn people suffer from asthma, which mainly affects childhood about 14% across the globe. Rising number of cases to various respiratory diseases elevate the demand for respiratory inhalers which uplift the growth of respiratory inhalers industry.

Moreover, researchers presented an acoustic inhaler technology at Respiratory Drug Delivery 2021 conference which was developed in UK, proposed viable alternative to more expensive respiratory electronic smart inhalers for respiratory disease management. This technology is expected to work sequential with smart phone which would help to detect acoustic signals and helps to provide feedback for the use of correct inhaler technique. This emerging technology is expected to improve inhaler techniques, and this will eventually decrease respiratory distress episodes. Such innovative and appropriate inhalers are expected to leverage the growth of respiratory inhalers industry.

Covid-19 pandemic has positively impacted the growth of respiratory inhalers market. Respiratory inhalers gained immense importance after sudden covid-19 outbreak. The rising demand for inhalers leveraged the growth of respiratory inhalers industry.

Global Respiratory Inhalers Market by Region Outlook (Revenue, USD Million, 2021-2027)

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Based on region, Asia-Pacific is anticipated to observe the highest market growth during the forecast period due to increase in urbanization and product diversification in this region, growing adoption of respiratory devices and growing R&D facilities boost the growth of the global respiratory inhalers industry in this region.

The Global Respiratory Inhalers Market Segmentation:

Global Respiratory Inhalers Market by Product Type Outlook (Revenue, USD Million, 2021-2027)

• Dry Powder Inhalers
• Metered Dose Inhalers
• Soft Mist Inhaler

Global Respiratory Inhalers Market by Patients Type Outlook (Revenue, USD Million, 2021-2027)

• Paediatric
• Adults

Global Respiratory Inhalers Market by Distribution Channel Type Outlook (Revenue, USD Million, 2021-2027)

• Hospitals
• Pharmacies
• Respiratory Care Center
• Online Pharmacies

Key Findings:

• Based on product, dry powder inhalers are expected to dominate the market during forecast period due to increase in adaption of dry powder-based formulations
• Based on patients, paediatric segment is expected to observe the fastest growth during the forecast period  
• Based on distribution channel, pharmacies is expected to hold the largest market share during forecast period. However, online pharmacies are expected to witness fastest growth with highest CAGR
• Based on region, North America is expected to hold highest market share during forecast period. However, Asia-Pacific is expected to witness fastest growth with highest CAGR during forecast period 

Company Profiles and Competitive Intelligence

The key players operating in the respiratory inhalers market market are:

• Cipla
• GSK
• Novartis
• Boehringer Ingelheim
• Astrazeneca
• Propeller Health
• Beximco Pharmaceuticals
• H&t Presspart
• Cohero Health
• Chiesi Farmaceutici
• Mundipharma
• 3m
• Heltman Medikal
• Adherium
• Luckys Pharma
• Amiko Digital Health
• Teva Pharmaceutical Industries
• Findair Sp. Z O. O.
• Vectura Group
• GlaxoSmithKline plc
• Koninklijke Philips N.V.
• Merck & Co., Inc
• Omron Healthcare Europe B.V
• PARI Medical Holding

Recent News:

• In June 2021, Glenmark Pharma launched tiotropium bromide dry powder inhaler for obstructive pulmonary disease in UK. COPD is the long-term diseases that causes inflammation in the lungs causing difficulty in breathing. Glenmark and its subsidiary Glenmark Pharmaceuticals Europe Ltd entered strategic licensing for commercializing and marketing of generic Tiotropium Bromide DPI in western region of Europe and UK.
• In October 2020, Teva Respiratory, LLC collaborated with Amazon Web Service and Onica to build digital healthcare platform. Moreover, Teva’s digital health platform is a cloud-based data system that is currently being supported by Digihaler® portfolio that is breath-actuated digital inhalers that contain sensors and bluetooth wireless technologies. This technology will help to track inhaler events and respiratory flow of the patient.
• In October 2020, Cadila Healthcare launched first ever pressurized metered dose inhaler for patients suffering COPD. The company raised 4.0% on the launch of the product in 52-week period. The product was developed for patients suffering from COPD. The product named ‘Forglyn pMDI’ in combination with LAMA and LABA for COPD.